A retrospective, adjusted analysis of people in China with type 2 diabetes significantly linked SGLT2 inhibitor use with a lower risk of gout compared with those receiving a DPP4 inhibitor.
A comprehensive meta-analysis finds cardiovascular improvement across age, sex, and race/ethnicity for high-risk individuals with type 2 diabetes and other CVD risk factors.
SGLT2 Inhibitors in Primary Care: All Hands on Deck medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as appalling and devastating , with questions raised as to why it was pulled.